• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Short-term freedom from disease progression after I-125 prostate implantation.

作者信息

Wallner K, Roy J, Zelefsky M, Fuks Z, Harrison L

机构信息

Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021.

出版信息

Int J Radiat Oncol Biol Phys. 1994 Sep 30;30(2):405-9. doi: 10.1016/0360-3016(94)90021-3.

DOI:10.1016/0360-3016(94)90021-3
PMID:7523345
Abstract

PURPOSE

To evaluate short-term clinical and chemical disease progression following computed tomography (CT)-based transperineal I-125 prostate implantation.

METHODS AND MATERIALS

Sixty-two patients with clinical Stage T1 or T2 prostatic carcinoma had outpatient, CT-based transperineal I-125 prostate implantation and have been followed for 6-55 months (median: 19 months). Fifty-six patients had an elevated prostate specific antigen (PSA) before implantation (> 4.0 ng/mL). Twenty patients had well-differentiated tumors, 39 were moderately differentiated, 2 were poorly differentiated, and 1 was indeterminate. A total of 32-73 mCi I-125 was implanted (median: 47 mCi). The prescribed minimum prostatic dose was 140-160 Gy, and the actual matched peripheral dose ranged from 109-258 Gy (median: 160 Gy). Lymph node dissection or postimplantation prostatic biopsies were not routinely performed.

RESULTS

Of 54 patients with an elevated PSA prior to implantation and no prior hormonal treatment, 96% returned to normal within 24 months of treatment. In 85% of patients, the PSA fell below 2.0 ng/mL and in 74% of patients, the PSA value fell to below 1.0 ng/mL. Seven patients had disease progression, one of whom has an isolated, rising PSA. The actuarial rate of chemical (rising PSA) or clinical failure at 3 years following implantation was 17%. Of 38 patients who were sexually potent prior to implantation, 81% remained potent at 3 years. Five patients developed radiation-induced rectal ulcerations, 11-22 months following implantation. Three patients required a transurethral resection of the prostate for postimplant urinary symptoms.

CONCLUSIONS

The short-term clinical and chemical freedom-from-progression rates following I-125 implantation are comparable to that achieved with prostatectomy, with high preservation of sexual potency and moderate morbidity.

摘要

相似文献

1
Short-term freedom from disease progression after I-125 prostate implantation.
Int J Radiat Oncol Biol Phys. 1994 Sep 30;30(2):405-9. doi: 10.1016/0360-3016(94)90021-3.
2
Prostate specific antigen based disease control following ultrasound guided 125iodine implantation for stage T1/T2 prostatic carcinoma.
J Urol. 1995 Sep;154(3):1096-9.
3
Tumor control and morbidity following transperineal iodine 125 implantation for stage T1/T2 prostatic carcinoma.
J Clin Oncol. 1996 Feb;14(2):449-53. doi: 10.1200/JCO.1996.14.2.449.
4
Prostate specific antigen findings and biopsy results following interactive ultrasound guided transperineal brachytherapy for early stage prostate carcinoma.早期前列腺癌经会阴超声引导下交互式近距离放射治疗后的前列腺特异性抗原结果及活检结果
Cancer. 1996 Jun 1;77(11):2386-92. doi: 10.1002/(SICI)1097-0142(19960601)77:11<2386::AID-CNCR30>3.0.CO;2-R.
5
Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality.前列腺近距离放射治疗后5年最低随访期的生化结果:患者选择和植入质量的重要性。
Int J Radiat Oncol Biol Phys. 2003 Nov 1;57(3):645-53. doi: 10.1016/s0360-3016(03)00627-8.
6
Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.前列腺临床器官局限性癌永久性组织间近距离放疗后活检阳性率与生化结果的关系。
Int J Radiat Oncol Biol Phys. 2002 Mar 1;52(3):664-73. doi: 10.1016/s0360-3016(01)02670-0.
7
Isotope selection for patients undergoing prostate brachytherapy.前列腺近距离放射治疗患者的同位素选择
Int J Radiat Oncol Biol Phys. 1999 Sep 1;45(2):391-5. doi: 10.1016/s0360-3016(99)00187-x.
8
PSA kinetics following I-125 radioactive seed implantation in the treatment of T1-T2 prostate cancer.
Radiat Oncol Investig. 1999;7(1):30-5. doi: 10.1002/(SICI)1520-6823(1999)7:1<30::AID-ROI4>3.0.CO;2-8.
9
Interstitial iodine-125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma.间质内碘-125放射治疗无辅助治疗用于临床局限性前列腺癌的治疗
Cancer. 1997 Aug 1;80(3):442-53. doi: 10.1002/(sici)1097-0142(19970801)80:3<442::aid-cncr12>3.0.co;2-x.
10
Prostate brachytherapy: treatment strategies.前列腺近距离放射治疗:治疗策略
J Urol. 1999 Aug;162(2):421-6. doi: 10.1016/s0022-5347(05)68574-6.

引用本文的文献

1
Difference in the rate of rectal complications following prostate brachytherapy based on the prostate-rectum distance and the prostate longitudinal length among early prostate cancer patients.早期前列腺癌患者中,基于前列腺与直肠的距离以及前列腺纵轴长度,前列腺近距离放射治疗后直肠并发症发生率的差异。
Korean J Urol. 2015 Sep;56(9):637-43. doi: 10.4111/kju.2015.56.9.637. Epub 2015 Sep 2.
2
Radiobiological effect induced by different activities of (125)I seed brachytherapy in a hepatocellular carcinoma model.(125)I粒子近距离放射治疗不同活度在肝癌模型中诱导的放射生物学效应
Int J Clin Exp Med. 2014 Dec 15;7(12):5260-7. eCollection 2014.
3
Advances in brachytherapy.
近距离放射治疗的进展。
Rev Urol. 2004;6 Suppl 4(Suppl 4):S37-48.
4
Iridium 192 high-dose-rate brachytherapy--a useful alternative therapy for localized prostate cancer?铱192高剂量率近距离放射疗法——一种用于局限性前列腺癌的有效替代疗法?
World J Urol. 1997;15(4):252-6. doi: 10.1007/BF01367663.
5
Imaging of prostate cancer.
Abdom Imaging. 1995 Nov-Dec;20(6):505-15. doi: 10.1007/BF01256700.